Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients JOURNAL OF INFECTIOUS DISEASES Chary, A., Winters, M. A., Kottilil, S., Murphy, A. A., Polis, M. A., Holodniy, M. 2010; 202 (6): 889-893

Abstract

Patients with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection for whom prior treatment of HCV with interferon-ribavirin has failed may require subsequent treatment with new HCV protease inhibitors (PIs). We evaluated the diversity of HCV nonstructural protein 3 (NS3) in 26 HCV- and HIV-coinfected patients receiving stable antiretroviral therapy (ART) who were treated with interferon-ribavirin. Plasma HCV RNA clonal analysis was performed. There was greater baseline NS3 diversity in patients with nonresponse or relapse than in those with sustained virologic response. Interferon-ribavirin treatment did not result in significant changes in HCV protease gene diversity or significant HCV PI resistance mutations. The effect of prior interferon-ribavirin treatment on HCV NS3 will likely not impact HCV PI efficacy in HIV-coinfected patients receiving ART.

View details for DOI 10.1086/655784

View details for Web of Science ID 000281091200010

View details for PubMedID 20677940